HOME >> BIOLOGY >> NEWS
Small animal imaging gives cancer clues

Advances in biomedical imaging are allowing UC Davis researchers to use mice more effectively to study cancers comparable to human disease. The system can distinguish different stages of cancer and could lead to more sensitive screening tests for cancer-fighting drugs.

Positron emission tomography (PET) is widely used for detecting and following cancer in human patients. It works by following short-lived radioactive tracers that are taken up by fast-growing cancer cells.

PET scanners used for humans don't have the resolution to image an animal as small as a mouse. Researchers led by Simon Cherry, a professor of biomedical engineering at UC Davis, have developed a PET scanner sensitive enough to use with mice, and Craig Abbey, also in the Department of Biomedical Engineering, has developed image analysis methods to use the scanner to monitor tumors.

They're working with cancer researchers Alexander Borowsky, Robert Cardiff and Jeffrey Gregg at the UC Davis Center for Comparative Medicine to study cancerous growths in mice similar to ductal carcinoma in situ (DCIS), a precursor to breast cancer in humans.

"With non-invasive imaging, we can follow the development of disease in one mouse over a long time period," Abbey said. The method is also more sensitive to changes in cancer growth, making it possible to look for small treatment effects.

Most invasive breast cancers are thought to develop from DCIS, and standard care is to remove the entire area involved, Borowsky said. Based on the appearance of a DCIS under the microscope, doctors can estimate how quickly it could become a more aggressive, invasive form if not completely removed, he said. The new PET technology allows researchers to follow the same changes in a mouse without surgery.

"Not only can we see the DCIS-like lesion, but we can detect the earliest transition to an invasive tumor," Borowsky said. The model
'"/>

Contact: Andy Fell
ahfell@ucdavis.edu
530-752-4533
University of California - Davis
9-Aug-2004


Page: 1 2

Related biology news :

1. Small, Smac-like molecule encourages death of cancer cells
2. Small RNA surmounts large cancer problem
3. Small, cold, & hungry: Ultra-small microbes from 120,000-year-old glacier ice sample
4. Small trial shows daclizumab add-on therapy improves MS outcome
5. Small gene changes in some leukemia patients may explain varying responses to chemotherapy
6. Small amounts of alcohol or anesthetics may damage the developing brain
7. Smallpox in 50-year-old tissues detected by integrated diagnostics approach
8. Small-molecule inhibitors of anthrax lethal factor identified
9. Smallpox in Europe selected for genetic mutation that confers resistance to HIV infection
10. Small-molecule inhibitors of botulinum neurotoxin identified
11. Smallest whirlpools can pack stunningly strong force

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Small animal imaging gives cancer clues

(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... 25, 2014 Lawrence Livermore scientists Charles ... Reuters list of " The World's Most Influential Scientific ... the 3,000 researchers who were identified by analyzing citation ... who published the highest-impact work (2002-2012 and 2012-2013). The ... combustion modeling . , "This recognition is a ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
Cached News: